



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12P 19/34, 21/00, C12N 15/11, C07H 21/04		A1	(11) International Publication Number: WO 99/37797
		(43) International Publication Date: 29 July 1999 (29.07.99)	
(21) International Application Number: PCT/US99/01462		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 25 January 1999 (25.01.99)		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(30) Priority Data: 60/122,053 26 January 1998 (26.01.98) US 60/080,036 31 March 1998 (31.03.98) US			
(71) Applicant (for all designated States except US): GENZYME CORPORATION [US/US]; One Mountain Road, P.O. Box 9322, Framingham, MA 01701-9322 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): ROBERTS, Bruce, L. [US/US]; 26 Windsor Road, Milford, MA 01757 (US). NICOLETTE, Charles, A. [US/US]; 52 Vega Road, Marlborough, MA 01752 (US).			
(74) Agents: KONSKI, Antoinette, F. et al.; Morrison & Foerster, LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).			
(54) Title: ANTIGEN-SPECIFIC CELLS, METHODS OF GENERATING THESE CELLS AND USES THEREOF			
(57) Abstract <p>The present invention provides methods for identifying antigens recognized by immune effector cells. In one embodiment, the methods combine identifying amino acid sequence motifs of such antigens and the DNA sequences that potentially encode the identified amino acid motifs and the DNA sequences which are aberrantly expressed in the cells. By comparison of these sequences, novel antigens that are recognized by immune effector cells are identified.</p>			